3月6日,宜明昂科-B(01541)发布公告,本公司已获得中华人民共和国国家药品监督管理局批准进行IMM01(替达派西普)联合IMM2510(珀维拉芙普α),另加化疗或不加化疗用于治疗晚期恶性肿瘤的临床试验。这一进展标志着公司在推进IMM01及IMM2510的临床研究方面取得了重要里程碑。IMM01是公司核心产品,作为中国首个进入临床阶段的SIRPα-Fc融合蛋白,具有良好的安全性并已获得美国食品...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.